S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Top 10 Searched Stocks on MarketBeat All-Access
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NASDAQ:GRFS

Grifols - GRFS Stock Forecast, Price & News

$7.95
-0.10 (-1.24%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.89
▼
$8.23
50-Day Range
$5.95
▼
$8.47
52-Week Range
$5.71
▼
$13.34
Volume
793,425 shs
Average Volume
1.07 million shs
Market Capitalization
$5.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.52

Grifols MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
57.5% Upside
$12.52 Price Target
Short Interest
Bearish
2.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Grifols in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
57.69%
From $0.52 to $0.82 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

614th out of 1,027 stocks

Pharmaceutical Preparations Industry

289th out of 503 stocks

See Top Rated MarketRank™ Stocks Here
GRFS stock logo

About Grifols (NASDAQ:GRFS) Stock

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum-from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring-to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Receive GRFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

GRFS Stock News Headlines

November 3, 2022 | finance.yahoo.com
Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1
October 17, 2022 | finance.yahoo.com
Serological Testing Market Report (2022 to 2030) - Abbott Laboratories Inc., Grifols, S.A., Sysmex Corporation, Thermo Fisher Scientific Inc and Siemens Healthineers AG - Yahoo Finance
December 8, 2022 | Investing Trends (Ad)
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race
Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China enjoyed a "near monopoly" in this vital ingredient... until the U.S. made a blockbuster announcement. Now one little-known company is set to play a crucial role in the booming $7 trillion EV revolution.
October 15, 2022 | globenewswire.com
Molecular Diagnostics Market Size to Worth Around USD 48.9 Bn by 2030 - GlobeNewswire
October 11, 2022 | benzinga.com
Blood Market Size to Grow by USD 1.82 Bn, Whole Blood Collection and Processing to be Largest Revenue-gen - Benzinga
October 3, 2022 | benzinga.com
Victor Grifols Roura Decides To Retire As Chair-Person; Grifols Appoints Private Equity Veteran Steven F. - Benzinga
October 3, 2022 | reuters.com
Grifols appoints executive chairman as seeks to speed recovery - Reuters
October 3, 2022 | finance.yahoo.com
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson
December 8, 2022 | Investing Trends (Ad)
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race
Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China enjoyed a "near monopoly" in this vital ingredient... until the U.S. made a blockbuster announcement. Now one little-known company is set to play a crucial role in the booming $7 trillion EV revolution.
September 27, 2022 | thestreet.com
Warren Buffett's Berkshire Makes List of Undervalued, Stocks - TheStreet
September 26, 2022 | morningstar.com
6 Undervalued Stocks With Low Beta - Morningstar
September 26, 2022 | streetinsider.com
Form 6-K Grifols SA For: Sep 26 - StreetInsider.com
September 26, 2022 | nasdaq.com
Spain's Grifols sees second-half revenues growing at two-digit rate - Nasdaq
September 23, 2022 | finance.yahoo.com
Plasma Fractionation Market Worth $46.9 Billion by 2029- Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research® - Yahoo Finance
September 22, 2022 | benzinga.com
Plasma Fractionation Market Worth $46.9 Billion by 2029- Market Size, Share, Forecasts, & Trends Analysis - Benzinga
September 22, 2022 | globenewswire.com
Blood Group Typing market worth USD 3 Billion by 2030, says Global Market Insights Inc. - GlobeNewswire
September 22, 2022 | globenewswire.com
Toothbrush Market to Reach USD 9.14 Billion by 2029 | Toothbrush Industry Striking CAGR of 4.1% - GlobeNewswire
September 22, 2022 | finance.yahoo.com
Toothbrush Market to Reach USD 9.14 Billion by 2029 | Toothbrush Industry Striking CAGR of 4.1% - Yahoo Finance
September 17, 2022 | theglobeandmail.com
Ontario and B.C. decline to endorse Canadian Blood Services' view that private firm can circumvent collection ban - The Globe and Mail
September 15, 2022 | globenewswire.com
Antithrombin Market is estimated to be US$ 849.87 million by 2030 with a CAGR of 4.3% during the forecast period 2030 - By PMI - GlobeNewswire
September 14, 2022 | nasdaq.com
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Nasdaq
September 13, 2022 | businesswire.com
$119 Billion Worldwide Contract Research and Manufacturing Services Industry to 2031 - Rising Aging Population With Various Chronic Diseases is Expected to Have a Positive Impact - ResearchAndMarkets.com - Business Wire
September 8, 2022 | globenewswire.com
Disposable Blood Bag Market Size to Hit US$ 283.47 Bn by 2028, at a 4.70% CAGR - Comprehensive Research Report by Facts & Factors - GlobeNewswire
September 7, 2022 | seekingalpha.com
Grifols inks 15-year deal with Canada for plasma-derived therapies (NASDAQ:GRFS) - Seeking Alpha
September 7, 2022 | finance.yahoo.com
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
September 6, 2022 | benzinga.com
With 6.2% CAGR, Intravenous Immunoglobulins Market Size worth USD 15,789.1 Million in 2025 - Benzinga
September 2, 2022 | globenewswire.com
Immunoglobulin Market to value US$ 23.1 billion by 2030, Says Growth Plus Reports - GlobeNewswire
See More Headlines
Receive GRFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

GRFS Company Calendar

Last Earnings
5/04/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRFS
CUSIP
N/A
CIK
1438569
Web
www.grifols.com
Phone
(493) 571-2200
Fax
34-93-571-0267
Employees
23,234
Year Founded
1909

Price Target and Rating

Average Stock Price Forecast
$12.52
High Stock Price Forecast
$20.30
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+57.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
1.20
Current Ratio
2.68
Quick Ratio
0.91

Sales & Book Value

Annual Sales
$5.84 billion
Price / Sales
0.94
Cash Flow
$1.01 per share
Price / Cash Flow
7.91
Book Value
$12.59 per share
Price / Book
0.63

Miscellaneous

Outstanding Shares
687,550,000
Free Float
686,249,000
Market Cap
$5.47 billion
Optionable
Optionable
Beta
0.49

Social Links


Key Executives

  • Mr. Steven Francis Mayer J.D. (Age 62)
    Exec. Chairman
    Comp: $129.29k
  • Mr. Raimon Grifols Roura (Age 58)
    Co-CEO & Exec. Director
    Comp: $925.72k
  • Mr. Víctor Grifols Deu (Age 45)
    Co-CEO & Exec. Director
    Comp: $925.72k
  • Mr. Alfredo Arroyo Guerra (Age 64)
    CFO & VP
  • Mrs. Eva Bastida Tubau
    Corp. VP and Director of Scientific & Medical Affairs
  • Ms. Nuria Pascual Lapeña (Age 58)
    VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer
  • Mr. David Ian Bell (Age 68)
    Gen. Counsel & Chief Corp. Devel. Officer
  • Mr. Mateo Florencio Borrás Humbert (Age 66)
    Corp. VP & Chief HR Officer
  • Ms. Maria Teresa-Rioné Llano (Age 57)
    Chief Communications Officer
  • Ms. Montserrat Gaja Llamas (Age 57)
    Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













GRFS Stock - Frequently Asked Questions

Should I buy or sell Grifols stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GRFS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRFS, but not buy additional shares or sell existing shares.
View GRFS analyst ratings or view top-rated stocks.

What is Grifols' stock price forecast for 2023?

6 brokers have issued twelve-month price targets for Grifols' shares. Their GRFS share price forecasts range from $9.00 to $20.30. On average, they anticipate the company's stock price to reach $12.52 in the next year. This suggests a possible upside of 57.5% from the stock's current price.
View analysts price targets for GRFS or view top-rated stocks among Wall Street analysts.

How have GRFS shares performed in 2022?

Grifols' stock was trading at $11.23 on January 1st, 2022. Since then, GRFS stock has decreased by 29.2% and is now trading at $7.95.
View the best growth stocks for 2022 here.

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) issued its earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by $0.01. The biotechnology company earned $1.43 billion during the quarter.

When did Grifols' stock split?

Grifols's stock split on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were payable to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols Chief Executive Officer Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Grifols own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Grifols investors own include Gilead Sciences (GILD), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Johnson & Johnson (JNJ), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR).

What is Grifols' stock symbol?

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Who are Grifols' major shareholders?

Grifols' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Brandes Investment Partners LP (0.93%), Flat Footed LLC (0.81%), Pictet Asset Management SA (0.71%), First Trust Advisors LP (0.64%), State Street Corp (0.46%) and Point72 Asset Management L.P. (0.35%).

How do I buy shares of Grifols?

Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Grifols' stock price today?

One share of GRFS stock can currently be purchased for approximately $7.95.

How much money does Grifols make?

Grifols (NASDAQ:GRFS) has a market capitalization of $5.47 billion and generates $5.84 billion in revenue each year.

How many employees does Grifols have?

The company employs 23,234 workers across the globe.

Does Grifols have any subsidiaries?
The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..
Read More
How can I contact Grifols?

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The official website for the company is www.grifols.com. The biotechnology company can be reached via phone at (493) 571-2200, via email at inversores@grifols.com, or via fax at 34-93-571-0267.

This page (NASDAQ:GRFS) was last updated on 12/8/2022 by MarketBeat.com Staff